SBI-183

• Description:

  SBI-183 is an orally active inhibitor of QSOX1 (Kd: 20 μM) . SBI-183 suppresses the proliferative and invasive phenotype of renal cancer cell lines, including triple negative breast cancer cell line, lung adenocarcinoma cell line and pancreatic ductal adenocarcinoma. SBI-183 inhibits tumor growth in two human xenograft mouse models of renal cell carcinoma in vivo [1].

• UNSPSC:

  12352005

• Target:

  Transmembrane Glycoprotein

• Type:

  Reference compound

• Related Pathways:

  Immunology/Inflammation

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/sbi-183.html

• Purity:

  99.8

• Smiles:

  O=C(C1=CC(OC)=CC=C1)NC2=CC=C(N3CCCC3)C=C2

• Molecular Formula:

  C18H20N2O2

• Molecular Weight:

  296.36

• References & Citations:

  [1]Fifield, et al. Molecular Inhibitor of QSOX1 Suppresses Tumor Growth In Vivo. Molecular cancer therapeutics. 2020, 19 (1), 112–122.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [625403-59-0]